Información del producto
- Ro 42-5892
- (αS)-N-[(1S,2R,3S)-1-(Cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-α-[[(2S)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-5-propanamide
- 1H-Imidazole-4-propanamide, N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-α-[[(2S)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-, (αS)-
- 1H-Imidazole-4-propanamide, N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-α-[[2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-, [1S-[1R*[R*(R*)],2S*,3R*]]-
- 1H-Imidazole-5-propanamide, N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-α-[[(2S)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-, (αS)-
Remikiren is an angiotensin receptor blocker that blocks the binding of angiotensin II to its receptors on cells. It is used to treat high blood pressure and congestive heart failure. Remikiren has been shown to have a low potency in vitro, but it is more potent in vivo and has greater efficacy than losartan at doses of 100 mg/kg/day. This drug also has biochemical properties that are similar to those of other inhibitors of the renin-angiotensin system, such as ACE inhibitors and AT1 antagonists. Remikiren significantly reduces the level of angiotensin II in animals with experimental cardiac disease, which may be due to its ability to inhibit cytokine production by macrophages.
Propiedades químicas
Consulta técnica sobre: 3D-BFA22234 Remikiren
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.